Impact of a homeopathic medication on upper respiratory tract infections in COPD patients: Results of an observational, prospective study (EPOXILO).
Identifieur interne : 000034 ( Main/Exploration ); précédent : 000033; suivant : 000035Impact of a homeopathic medication on upper respiratory tract infections in COPD patients: Results of an observational, prospective study (EPOXILO).
Auteurs : Susana Conde Diez [Espagne] ; Ana Viejo Casas [Espagne] ; Juan Luis Garcia Rivero [Espagne] ; Juan Carlos Lopez Caro [Espagne] ; Felix Ortiz Portal [Espagne] ; Gualberto Diaz Saez [Espagne]Source :
- Respiratory medicine [ 1532-3064 ] ; 2019.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Broncho-pneumopathie chronique obstructive (complications), Broncho-pneumopathie chronique obstructive (traitement médicamenteux), Espagne (épidémiologie), Femelle (MeSH), Homéopathie (MeSH), Hormones corticosurrénaliennes (effets indésirables), Hormones corticosurrénaliennes (usage thérapeutique), Humains (MeSH), Infections de l'appareil respiratoire (prévention et contrôle), Infections de l'appareil respiratoire (épidémiologie), Modèles logistiques (MeSH), Qualité de vie (MeSH), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Études cas-témoins (MeSH), Études prospectives (MeSH).
- MESH :
- effets indésirables : Broncho-pneumopathie chronique obstructive, Hormones corticosurrénaliennes.
- prévention et contrôle : Infections de l'appareil respiratoire.
- traitement médicamenteux : Broncho-pneumopathie chronique obstructive.
- usage thérapeutique : Hormones corticosurrénaliennes.
- épidémiologie : Espagne, Infections de l'appareil respiratoire.
- Adulte d'âge moyen, Femelle, Homéopathie, Humains, Modèles logistiques, Qualité de vie, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Études cas-témoins, Études prospectives.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adrenal Cortex Hormones (adverse effects), Adrenal Cortex Hormones (therapeutic use), Aged (MeSH), Aged, 80 and over (MeSH), Case-Control Studies (MeSH), Female (MeSH), Homeopathy (MeSH), Humans (MeSH), Logistic Models (MeSH), Middle Aged (MeSH), Prospective Studies (MeSH), Pulmonary Disease, Chronic Obstructive (complications), Pulmonary Disease, Chronic Obstructive (drug therapy), Quality of Life (MeSH), Respiratory Tract Infections (epidemiology), Respiratory Tract Infections (prevention & control), Spain (epidemiology), Treatment Outcome (MeSH).
- MESH :
- chemical , adverse effects : Adrenal Cortex Hormones.
- chemical , therapeutic use : Adrenal Cortex Hormones.
- geographic , epidemiology : Spain.
- complications : Pulmonary Disease, Chronic Obstructive.
- drug therapy : Pulmonary Disease, Chronic Obstructive.
- epidemiology : Respiratory Tract Infections.
- prevention & control : Respiratory Tract Infections.
- Aged, Aged, 80 and over, Case-Control Studies, Female, Homeopathy, Humans, Logistic Models, Middle Aged, Prospective Studies, Quality of Life, Treatment Outcome.
Abstract
BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder in which airflow is obstructed. Viral or bacterial upper respiratory tract infections (URTIs) may lead to exacerbations. Homeopathic medication administration to COPD patients during the influenza-exposure period may help to reduce the frequency of common URTIs.
METHODS
This prospective, observational, multicenter study was carried out in Cantabria, Spain. Patients with COPD were divided into two groups: group 1 received conventional treatment + homeopathic medication (diluted and dynamized extract of duck liver and heart; Boiron) (OG); group 2 received conventional treatment only (CG). The primary endpoint was the number of URTIs between the 4-5 months follow up (mean 4.72 ± 0.96) from basal to last visit. Secondary endpoints included the duration of URTIs, number and duration of COPD exacerbations, use of COPD drugs, changes in quality of life (QoL), compliance, and adverse events (AEs).
RESULTS
219 patients were analyzed (OG = 109, CG = 110). There was a significant reduction in mean number of URTIs during the follow-up period in OG compared to CG (0.514 ± 0.722 vs. 1.037 ± 1.519, respectively; p = 0.014). Logistic regression analysis showed a 3.3-times higher probability of suffering ≥2 URTI episodes in CG (p = 0.003, n = 72). OG patients having ≥1 URTI also had a significant reduction in mean URTI duration per episode (3.57 ± 2.44 days OG vs. 5.22 ± 4.17 days CG; p = 0.012). There was no significant difference in mean number of exacerbations, mean duration of exacerbations, or QoL between OG and CG. There was a greater decrease in proportion of patients using corticosteroids for exacerbations between baseline and visit 2 in OG compared to CG (22.1% vs. 7.5% fewer respectively, p = 0.005). Exacerbator phenotype patients had a significant decrease in number of URTIs (0.54 ± 0.72 vs. 1.31 ± 1.81; p = 0.011), and fewer COPD exacerbations (0.9 ± 1.3 vs. 1.5 ± 1.7; p = 0.037) in OG vs. CG, respectively.
CONCLUSIONS
Homeopathic medication use during the influenza-exposure period may have a beneficial impact at reducing URTIs' number and duration in COPD patients and at reducing the number of COPD exacerbations in patients with the exacerbator phenotype. Further studies are needed to confirm the effects observed in this study.
DOI: 10.1016/j.rmed.2018.11.011
PubMed: 30665525
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of a homeopathic medication on upper respiratory tract infections in COPD patients: Results of an observational, prospective study (EPOXILO).</title><author><name sortKey="Conde Diez, Susana" sort="Conde Diez, Susana" uniqKey="Conde Diez S" first="Susana" last="Conde Diez">Susana Conde Diez</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Salud José Barros (Camargo), Avda. Bilbao S/n. Muriedas, 39600, Cantabria, Spain. Electronic address: sue_santander@yahoo.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Salud José Barros (Camargo), Avda. Bilbao S/n. Muriedas, 39600, Cantabria</wicri:regionArea><wicri:noRegion>Cantabria</wicri:noRegion></affiliation></author><author><name sortKey="Viejo Casas, Ana" sort="Viejo Casas, Ana" uniqKey="Viejo Casas A" first="Ana" last="Viejo Casas">Ana Viejo Casas</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Salud Pisueña-Cayón, C/El Ferial S/n. 39620 Sarón, Cantabria, Spain. Electronic address: afvcasas@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Salud Pisueña-Cayón, C/El Ferial S/n. 39620 Sarón, Cantabria</wicri:regionArea><wicri:noRegion>Cantabria</wicri:noRegion></affiliation></author><author><name sortKey="Garcia Rivero, Juan Luis" sort="Garcia Rivero, Juan Luis" uniqKey="Garcia Rivero J" first="Juan Luis" last="Garcia Rivero">Juan Luis Garcia Rivero</name><affiliation wicri:level="1"><nlm:affiliation>Servicio de Neumología, Hospital de Laredo, Cantabria, Spain. Electronic address: jgarcianml@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Neumología, Hospital de Laredo, Cantabria</wicri:regionArea><wicri:noRegion>Cantabria</wicri:noRegion></affiliation></author><author><name sortKey="Lopez Caro, Juan Carlos" sort="Lopez Caro, Juan Carlos" uniqKey="Lopez Caro J" first="Juan Carlos" last="Lopez Caro">Juan Carlos Lopez Caro</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Salud Cotolino, C/San Andrés S/n Castro Urdiales, 39700, Cantabria, Spain. Electronic address: jcarloslopezcaro@hotmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Salud Cotolino, C/San Andrés S/n Castro Urdiales, 39700, Cantabria</wicri:regionArea><wicri:noRegion>Cantabria</wicri:noRegion></affiliation></author><author><name sortKey="Ortiz Portal, Felix" sort="Ortiz Portal, Felix" uniqKey="Ortiz Portal F" first="Felix" last="Ortiz Portal">Felix Ortiz Portal</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: ortizportal@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Marqués de Valdecilla, Santander</wicri:regionArea><wicri:noRegion>Santander</wicri:noRegion></affiliation></author><author><name sortKey="Diaz Saez, Gualberto" sort="Diaz Saez, Gualberto" uniqKey="Diaz Saez G" first="Gualberto" last="Diaz Saez">Gualberto Diaz Saez</name><affiliation wicri:level="1"><nlm:affiliation>Former Medical Director, BOIRON SIH, Madrid, Spain; CEDH (Centro Enseñanza y Desarrollo Homeopatía), Alcobendas, Spain. Electronic address: diazgual@yahoo.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Former Medical Director, BOIRON SIH, Madrid, Spain; CEDH (Centro Enseñanza y Desarrollo Homeopatía), Alcobendas</wicri:regionArea><wicri:noRegion>Alcobendas</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30665525</idno><idno type="pmid">30665525</idno><idno type="doi">10.1016/j.rmed.2018.11.011</idno><idno type="wicri:Area/Main/Corpus">00028</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00028</idno><idno type="wicri:Area/Main/Curation">000028</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000028</idno><idno type="wicri:Area/Main/Exploration">000028</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of a homeopathic medication on upper respiratory tract infections in COPD patients: Results of an observational, prospective study (EPOXILO).</title><author><name sortKey="Conde Diez, Susana" sort="Conde Diez, Susana" uniqKey="Conde Diez S" first="Susana" last="Conde Diez">Susana Conde Diez</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Salud José Barros (Camargo), Avda. Bilbao S/n. Muriedas, 39600, Cantabria, Spain. Electronic address: sue_santander@yahoo.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Salud José Barros (Camargo), Avda. Bilbao S/n. Muriedas, 39600, Cantabria</wicri:regionArea><wicri:noRegion>Cantabria</wicri:noRegion></affiliation></author><author><name sortKey="Viejo Casas, Ana" sort="Viejo Casas, Ana" uniqKey="Viejo Casas A" first="Ana" last="Viejo Casas">Ana Viejo Casas</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Salud Pisueña-Cayón, C/El Ferial S/n. 39620 Sarón, Cantabria, Spain. Electronic address: afvcasas@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Salud Pisueña-Cayón, C/El Ferial S/n. 39620 Sarón, Cantabria</wicri:regionArea><wicri:noRegion>Cantabria</wicri:noRegion></affiliation></author><author><name sortKey="Garcia Rivero, Juan Luis" sort="Garcia Rivero, Juan Luis" uniqKey="Garcia Rivero J" first="Juan Luis" last="Garcia Rivero">Juan Luis Garcia Rivero</name><affiliation wicri:level="1"><nlm:affiliation>Servicio de Neumología, Hospital de Laredo, Cantabria, Spain. Electronic address: jgarcianml@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Neumología, Hospital de Laredo, Cantabria</wicri:regionArea><wicri:noRegion>Cantabria</wicri:noRegion></affiliation></author><author><name sortKey="Lopez Caro, Juan Carlos" sort="Lopez Caro, Juan Carlos" uniqKey="Lopez Caro J" first="Juan Carlos" last="Lopez Caro">Juan Carlos Lopez Caro</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Salud Cotolino, C/San Andrés S/n Castro Urdiales, 39700, Cantabria, Spain. Electronic address: jcarloslopezcaro@hotmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Salud Cotolino, C/San Andrés S/n Castro Urdiales, 39700, Cantabria</wicri:regionArea><wicri:noRegion>Cantabria</wicri:noRegion></affiliation></author><author><name sortKey="Ortiz Portal, Felix" sort="Ortiz Portal, Felix" uniqKey="Ortiz Portal F" first="Felix" last="Ortiz Portal">Felix Ortiz Portal</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: ortizportal@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Marqués de Valdecilla, Santander</wicri:regionArea><wicri:noRegion>Santander</wicri:noRegion></affiliation></author><author><name sortKey="Diaz Saez, Gualberto" sort="Diaz Saez, Gualberto" uniqKey="Diaz Saez G" first="Gualberto" last="Diaz Saez">Gualberto Diaz Saez</name><affiliation wicri:level="1"><nlm:affiliation>Former Medical Director, BOIRON SIH, Madrid, Spain; CEDH (Centro Enseñanza y Desarrollo Homeopatía), Alcobendas, Spain. Electronic address: diazgual@yahoo.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Former Medical Director, BOIRON SIH, Madrid, Spain; CEDH (Centro Enseñanza y Desarrollo Homeopatía), Alcobendas</wicri:regionArea><wicri:noRegion>Alcobendas</wicri:noRegion></affiliation></author></analytic><series><title level="j">Respiratory medicine</title><idno type="eISSN">1532-3064</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (adverse effects)</term><term>Adrenal Cortex Hormones (therapeutic use)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Case-Control Studies (MeSH)</term><term>Female (MeSH)</term><term>Homeopathy (MeSH)</term><term>Humans (MeSH)</term><term>Logistic Models (MeSH)</term><term>Middle Aged (MeSH)</term><term>Prospective Studies (MeSH)</term><term>Pulmonary Disease, Chronic Obstructive (complications)</term><term>Pulmonary Disease, Chronic Obstructive (drug therapy)</term><term>Quality of Life (MeSH)</term><term>Respiratory Tract Infections (epidemiology)</term><term>Respiratory Tract Infections (prevention & control)</term><term>Spain (epidemiology)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Broncho-pneumopathie chronique obstructive (complications)</term><term>Broncho-pneumopathie chronique obstructive (traitement médicamenteux)</term><term>Espagne (épidémiologie)</term><term>Femelle (MeSH)</term><term>Homéopathie (MeSH)</term><term>Hormones corticosurrénaliennes (effets indésirables)</term><term>Hormones corticosurrénaliennes (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Infections de l'appareil respiratoire (prévention et contrôle)</term><term>Infections de l'appareil respiratoire (épidémiologie)</term><term>Modèles logistiques (MeSH)</term><term>Qualité de vie (MeSH)</term><term>Résultat thérapeutique (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Études cas-témoins (MeSH)</term><term>Études prospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adrenal Cortex Hormones</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenal Cortex Hormones</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Pulmonary Disease, Chronic Obstructive</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Pulmonary Disease, Chronic Obstructive</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Broncho-pneumopathie chronique obstructive</term><term>Hormones corticosurrénaliennes</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Respiratory Tract Infections</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Respiratory Tract Infections</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections de l'appareil respiratoire</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Broncho-pneumopathie chronique obstructive</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hormones corticosurrénaliennes</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term><term>Infections de l'appareil respiratoire</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Female</term><term>Homeopathy</term><term>Humans</term><term>Logistic Models</term><term>Middle Aged</term><term>Prospective Studies</term><term>Quality of Life</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Homéopathie</term><term>Humains</term><term>Modèles logistiques</term><term>Qualité de vie</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études cas-témoins</term><term>Études prospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder in which airflow is obstructed. Viral or bacterial upper respiratory tract infections (URTIs) may lead to exacerbations. Homeopathic medication administration to COPD patients during the influenza-exposure period may help to reduce the frequency of common URTIs.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>This prospective, observational, multicenter study was carried out in Cantabria, Spain. Patients with COPD were divided into two groups: group 1 received conventional treatment + homeopathic medication (diluted and dynamized extract of duck liver and heart; Boiron) (OG); group 2 received conventional treatment only (CG). The primary endpoint was the number of URTIs between the 4-5 months follow up (mean 4.72 ± 0.96) from basal to last visit. Secondary endpoints included the duration of URTIs, number and duration of COPD exacerbations, use of COPD drugs, changes in quality of life (QoL), compliance, and adverse events (AEs).</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>219 patients were analyzed (OG = 109, CG = 110). There was a significant reduction in mean number of URTIs during the follow-up period in OG compared to CG (0.514 ± 0.722 vs. 1.037 ± 1.519, respectively; p = 0.014). Logistic regression analysis showed a 3.3-times higher probability of suffering ≥2 URTI episodes in CG (p = 0.003, n = 72). OG patients having ≥1 URTI also had a significant reduction in mean URTI duration per episode (3.57 ± 2.44 days OG vs. 5.22 ± 4.17 days CG; p = 0.012). There was no significant difference in mean number of exacerbations, mean duration of exacerbations, or QoL between OG and CG. There was a greater decrease in proportion of patients using corticosteroids for exacerbations between baseline and visit 2 in OG compared to CG (22.1% vs. 7.5% fewer respectively, p = 0.005). Exacerbator phenotype patients had a significant decrease in number of URTIs (0.54 ± 0.72 vs. 1.31 ± 1.81; p = 0.011), and fewer COPD exacerbations (0.9 ± 1.3 vs. 1.5 ± 1.7; p = 0.037) in OG vs. CG, respectively.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Homeopathic medication use during the influenza-exposure period may have a beneficial impact at reducing URTIs' number and duration in COPD patients and at reducing the number of COPD exacerbations in patients with the exacerbator phenotype. Further studies are needed to confirm the effects observed in this study.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30665525</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-3064</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><PubDate><Year>2019</Year><Month>01</Month></PubDate></JournalIssue><Title>Respiratory medicine</Title><ISOAbbreviation>Respir Med</ISOAbbreviation></Journal><ArticleTitle>Impact of a homeopathic medication on upper respiratory tract infections in COPD patients: Results of an observational, prospective study (EPOXILO).</ArticleTitle><Pagination><MedlinePgn>96-105</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0954-6111(18)30370-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rmed.2018.11.011</ELocationID><Abstract><AbstractText Label="BACKGROUND">Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder in which airflow is obstructed. Viral or bacterial upper respiratory tract infections (URTIs) may lead to exacerbations. Homeopathic medication administration to COPD patients during the influenza-exposure period may help to reduce the frequency of common URTIs.</AbstractText><AbstractText Label="METHODS">This prospective, observational, multicenter study was carried out in Cantabria, Spain. Patients with COPD were divided into two groups: group 1 received conventional treatment + homeopathic medication (diluted and dynamized extract of duck liver and heart; Boiron) (OG); group 2 received conventional treatment only (CG). The primary endpoint was the number of URTIs between the 4-5 months follow up (mean 4.72 ± 0.96) from basal to last visit. Secondary endpoints included the duration of URTIs, number and duration of COPD exacerbations, use of COPD drugs, changes in quality of life (QoL), compliance, and adverse events (AEs).</AbstractText><AbstractText Label="RESULTS">219 patients were analyzed (OG = 109, CG = 110). There was a significant reduction in mean number of URTIs during the follow-up period in OG compared to CG (0.514 ± 0.722 vs. 1.037 ± 1.519, respectively; p = 0.014). Logistic regression analysis showed a 3.3-times higher probability of suffering ≥2 URTI episodes in CG (p = 0.003, n = 72). OG patients having ≥1 URTI also had a significant reduction in mean URTI duration per episode (3.57 ± 2.44 days OG vs. 5.22 ± 4.17 days CG; p = 0.012). There was no significant difference in mean number of exacerbations, mean duration of exacerbations, or QoL between OG and CG. There was a greater decrease in proportion of patients using corticosteroids for exacerbations between baseline and visit 2 in OG compared to CG (22.1% vs. 7.5% fewer respectively, p = 0.005). Exacerbator phenotype patients had a significant decrease in number of URTIs (0.54 ± 0.72 vs. 1.31 ± 1.81; p = 0.011), and fewer COPD exacerbations (0.9 ± 1.3 vs. 1.5 ± 1.7; p = 0.037) in OG vs. CG, respectively.</AbstractText><AbstractText Label="CONCLUSIONS">Homeopathic medication use during the influenza-exposure period may have a beneficial impact at reducing URTIs' number and duration in COPD patients and at reducing the number of COPD exacerbations in patients with the exacerbator phenotype. Further studies are needed to confirm the effects observed in this study.</AbstractText><CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conde Diez</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centro de Salud José Barros (Camargo), Avda. Bilbao S/n. Muriedas, 39600, Cantabria, Spain. Electronic address: sue_santander@yahoo.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viejo Casas</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Salud Pisueña-Cayón, C/El Ferial S/n. 39620 Sarón, Cantabria, Spain. Electronic address: afvcasas@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia Rivero</LastName><ForeName>Juan Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Servicio de Neumología, Hospital de Laredo, Cantabria, Spain. Electronic address: jgarcianml@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez Caro</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Centro de Salud Cotolino, C/San Andrés S/n Castro Urdiales, 39700, Cantabria, Spain. Electronic address: jcarloslopezcaro@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz Portal</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: ortizportal@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz Saez</LastName><ForeName>Gualberto</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Former Medical Director, BOIRON SIH, Madrid, Spain; CEDH (Centro Enseñanza y Desarrollo Homeopatía), Alcobendas, Spain. Electronic address: diazgual@yahoo.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Respir Med</MedlineTA><NlmUniqueID>8908438</NlmUniqueID><ISSNLinking>0954-6111</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006705" MajorTopicYN="N">Homeopathy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029424" MajorTopicYN="N">Pulmonary Disease, Chronic Obstructive</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Chronic obstructive pulmonary disease</Keyword><Keyword MajorTopicYN="Y">Exacerbation</Keyword><Keyword MajorTopicYN="Y">Homeopathy</Keyword><Keyword MajorTopicYN="Y">Influenza like illness</Keyword><Keyword MajorTopicYN="Y">Observational study</Keyword><Keyword MajorTopicYN="Y">Oscillococcinum(®)</Keyword><Keyword MajorTopicYN="Y">Upper respiratory tract infections</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>06</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30665525</ArticleId><ArticleId IdType="pii">S0954-6111(18)30370-6</ArticleId><ArticleId IdType="doi">10.1016/j.rmed.2018.11.011</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country></list><tree><country name="Espagne"><noRegion><name sortKey="Conde Diez, Susana" sort="Conde Diez, Susana" uniqKey="Conde Diez S" first="Susana" last="Conde Diez">Susana Conde Diez</name></noRegion><name sortKey="Diaz Saez, Gualberto" sort="Diaz Saez, Gualberto" uniqKey="Diaz Saez G" first="Gualberto" last="Diaz Saez">Gualberto Diaz Saez</name><name sortKey="Garcia Rivero, Juan Luis" sort="Garcia Rivero, Juan Luis" uniqKey="Garcia Rivero J" first="Juan Luis" last="Garcia Rivero">Juan Luis Garcia Rivero</name><name sortKey="Lopez Caro, Juan Carlos" sort="Lopez Caro, Juan Carlos" uniqKey="Lopez Caro J" first="Juan Carlos" last="Lopez Caro">Juan Carlos Lopez Caro</name><name sortKey="Ortiz Portal, Felix" sort="Ortiz Portal, Felix" uniqKey="Ortiz Portal F" first="Felix" last="Ortiz Portal">Felix Ortiz Portal</name><name sortKey="Viejo Casas, Ana" sort="Viejo Casas, Ana" uniqKey="Viejo Casas A" first="Ana" last="Viejo Casas">Ana Viejo Casas</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000034 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000034 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30665525
|texte= Impact of a homeopathic medication on upper respiratory tract infections in COPD patients: Results of an observational, prospective study (EPOXILO).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30665525" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |